Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables - Net (2020 - 2024)

Historic Receivables - Net for Janux Therapeutics (JANX) over the last 5 years, with Q2 2024 value amounting to $7.5 million.

  • Janux Therapeutics' Receivables - Net changed N/A to $7.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2020, which is N/A changed from last year.
  • Janux Therapeutics' Receivables - Net amounted to $7.5 million in Q2 2024.
  • Over the past 5 years, Janux Therapeutics' Receivables - Net peaked at $8.0 million during Q4 2020, and registered a low of $400000.0 during Q2 2021.
  • For the 5-year period, Janux Therapeutics' Receivables - Net averaged around $3.0 million, with its median value being $659500.0 (2023).
  • Data for Janux Therapeutics' Receivables - Net shows a peak YoY increase of 3512.5% (in 2024) and a maximum YoY decrease of 3512.5% (in 2024) over the last 5 years.
  • Janux Therapeutics' Receivables - Net (Quarter) stood at $8.0 million in 2020, then crashed by 95.0% to $400000.0 in 2021, then increased by 25.0% to $500000.0 in 2022, then skyrocketed by 60.0% to $800000.0 in 2023, then skyrocketed by 837.5% to $7.5 million in 2024.
  • Its Receivables - Net stands at $7.5 million for Q2 2024, versus $519000.0 for Q1 2024 and $800000.0 for Q1 2023.